That is my thinking as well. The Phase 2b trial with over 300 participants (not 30) went very well, and moving to 900 in Phase 3 with a nearly identical protocol is, mathematically speaking, almost a sure thing mathematically speaking to see a reproduction of the Phase 2b results in Phase 3. So, the risk sits outside of mathematical predictions
As many here have mentioned, there are no sure bets in Phase 3 trials, but I am at a loss as to what the high-IQ analysts internally at the big pharma could be imagining. Or perhaps OPT has rejected their multibillion-dollar advances.
Certainly, I'm thinking of big buy if OPT's stock gets into the 40s.
Interesting speculation that a low stock price may force OPT's hand into accepting a bad deal as the possibility of a CR is diminished.
- Forums
- ASX - By Stock
- OPT
- Ann: Opthea Completes Enrollment in Phase 3 Clinical Program
Ann: Opthea Completes Enrollment in Phase 3 Clinical Program, page-21
-
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
60.0¢ |
Change
0.005(0.84%) |
Mkt cap ! $732.5M |
Open | High | Low | Value | Volume |
59.0¢ | 60.3¢ | 58.5¢ | $820.4K | 1.376M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 57803 | 59.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
60.0¢ | 13918 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
17 | 57803 | 0.595 |
12 | 66807 | 0.590 |
17 | 65165 | 0.585 |
11 | 114341 | 0.580 |
5 | 324210 | 0.575 |
Price($) | Vol. | No. |
---|---|---|
0.600 | 13918 | 10 |
0.605 | 23258 | 11 |
0.610 | 38231 | 7 |
0.615 | 100528 | 7 |
0.620 | 333106 | 9 |
Last trade - 14.14pm 12/09/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |